---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-008907"
form_type: "8-K"
ticker: "TERN"
cik: "0001831363"
company_name: "Terns Pharmaceuticals, Inc."
filed_at: "2026-01-09T23:59:59+00:00"
generated_at: "2026-05-16T11:05:34.253530+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Terns announces $1.0B cash runway; TERN-701 pivotal trial planned late 2026/early 2027

## Summary
- Year-end 2025 unaudited cash ~$1.0B, expected to fund operations into 2031 including potential TERN-701 launch.
- Completed December 2025 public offering of 18.7M shares, gross proceeds ~$747.5M.
- TERN-701 granted FDA Fast Track for CML; CARDINAL trial enrolled 85+ patients as of Dec 8, 2025.
- 2026 milestones: pivotal dose selection and EOP2 FDA interaction mid-2026; updated CARDINAL data by 2H26; start 2L+ pivotal trial late 2026/early 2027.
- New CARDINAL cohort to evaluate TERN-701 500mg QD in patients with BCR-ABL mutations including T315I.

## SEC filing metadata
- accession: 0001193125-26-008907
- form_type: 8-K
- ticker: TERN
- cik: 0001831363
- company_name: Terns Pharmaceuticals, Inc.
- filed_at: 2026-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831363/000119312526008907/0001193125-26-008907-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831363/000119312526008907/d69982d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-008907
- JSON: https://secwatch.observer/filing/0001193125-26-008907.json
- Plain text: https://secwatch.observer/filing/0001193125-26-008907.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.